Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belrestotug plus dostarlimab versus placebo plus pembrolizumab in previously untreated PD-L1-high NSCLC
NL-OMON59084Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Belrestotug + dostarlimab with Placebo + pembrolizumab (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 1 more. Started Jan 2025; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59084.